AR044007A1 - Metodos para el tratamiento de la enfermedad de parkinson - Google Patents

Metodos para el tratamiento de la enfermedad de parkinson

Info

Publication number
AR044007A1
AR044007A1 ARP040101189A ARP040101189A AR044007A1 AR 044007 A1 AR044007 A1 AR 044007A1 AR P040101189 A ARP040101189 A AR P040101189A AR P040101189 A ARP040101189 A AR P040101189A AR 044007 A1 AR044007 A1 AR 044007A1
Authority
AR
Argentina
Prior art keywords
disease
parkinson
safinamide
treatment
methods
Prior art date
Application number
ARP040101189A
Other languages
English (en)
Inventor
Fariello Ruggero
Carlo Cattaneo
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals Inc filed Critical Newron Pharmaceuticals Inc
Publication of AR044007A1 publication Critical patent/AR044007A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Usos de safinamida, derivados de safinamida e inhibidores de MAO-B en tipos de tratamiento para la enfermedad de Parkinson. Más específicamente, métodos para tratar la enfermedad de Parkinson mediante la administración de safinamida, un derivado de safinamida o un inhibidor de MAO-B, en combinación con otros agentes o tratamientos para la enfermedad de Parkinson, tales como levodopa/IDP o agonistas de dopamida. Composiciones farmacéuticas, terapias de combinación y equipo para tratar un paciente que tiene la enfermedad de Parkinson.
ARP040101189A 2003-04-11 2004-04-07 Metodos para el tratamiento de la enfermedad de parkinson AR044007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
AR044007A1 true AR044007A1 (es) 2005-08-24

Family

ID=33159845

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101189A AR044007A1 (es) 2003-04-11 2004-04-07 Metodos para el tratamiento de la enfermedad de parkinson

Country Status (28)

Country Link
US (3) US8283380B2 (es)
EP (2) EP1613296B1 (es)
JP (2) JP2006522800A (es)
KR (2) KR101129015B1 (es)
CN (2) CN1771030A (es)
AR (1) AR044007A1 (es)
AT (1) ATE435012T1 (es)
AU (1) AU2004228782B2 (es)
BR (1) BRPI0409364A (es)
CA (1) CA2523188C (es)
CY (3) CY1109295T1 (es)
DE (1) DE602004021790D1 (es)
DK (2) DK2070526T3 (es)
ES (2) ES2326373T3 (es)
FR (1) FR15C0054I2 (es)
HU (1) HUS1500043I1 (es)
IL (2) IL171331A (es)
LU (1) LU92782I2 (es)
MX (1) MXPA05010873A (es)
NL (1) NL300752I2 (es)
NO (3) NO334316B1 (es)
NZ (1) NZ542910A (es)
PL (2) PL2070526T3 (es)
PT (2) PT2070526E (es)
RU (1) RU2342929C2 (es)
SI (2) SI2070526T1 (es)
TW (1) TWI340640B (es)
WO (1) WO2004089353A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20070276046A1 (en) * 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
RS51411B (sr) * 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US8772346B2 (en) 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
IN266803B (es) 2005-12-22 2015-06-03 Newron Pharm Spa
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
KR101491541B1 (ko) 2006-06-19 2015-02-09 뉴론 파마슈티칼즈 에스. 피. 에이. 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
TR201802576T4 (tr) * 2007-06-15 2018-03-21 Newron Pharm Spa Sübsti̇tüe edi̇lmi̇ş 2-[2-(feni̇l)eti̇lami̇no]alkanami̇t türevleri̇ ve bunlarin sodyum ve/veya kalsi̇yum kanal modülatörleri̇ olarak kullanimi
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
EP3257842B1 (en) 2007-12-11 2020-11-18 Newron Pharmaceuticals S.p.A. Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
CN101903021B (zh) * 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
PL2285769T3 (pl) 2008-06-02 2015-01-30 Generics Uk Ltd Sposób otrzymywania enancjomerycznie czystych amin
AU2009254929B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited An improved process for the preparation of amines
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
LT2563355T (lt) 2010-04-27 2016-09-26 Newron Pharmaceuticals S.P.A. Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013028639A1 (en) 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
RU2685718C2 (ru) 2012-10-22 2019-04-23 Сивитас Терапьютикс, Инк. Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN106659685B (zh) * 2014-04-21 2021-02-05 丝维塔斯治疗公司 快速减轻帕金森病中的运动波动
WO2016052928A1 (ko) * 2014-10-02 2016-04-07 한국과학기술연구원 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
KR20180041234A (ko) * 2015-08-27 2018-04-23 프렉스톤 테라퓨틱스 에스에이 레보도파로 유발된 이상운동증 치료용 뇌 침투성 크로몬 옥심 유도체
KR102889062B1 (ko) * 2016-03-17 2025-11-21 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USE OF HUMAN EXCREMENTS AND SECRETIONS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
CA3072994A1 (en) * 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
CA3080975A1 (en) 2017-11-02 2019-05-09 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
DK4027815T5 (en) * 2019-09-12 2026-08-03 Achieve Life Sciences Inc Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
LU101477B1 (en) * 2019-11-12 2021-05-14 Univ Luxembourg An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
US20230028539A1 (en) * 2019-12-06 2023-01-26 Shanghai Pharmaceuticals Holding Co., Ltd. Pharmaceutical composition, complementary kit and application thereof
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) * 2020-08-31 2022-03-03 Purdue Pharma L.P. Compositions and methods for levodopa delivery
KR20230154249A (ko) * 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제
CN117615768A (zh) * 2021-06-24 2024-02-27 韦斯特兰德特斯创新股份公司 用于帕金森病的nad增效疗法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
DE3779500T2 (de) * 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
CA1336169C (en) 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
IL216403A (en) 2015-01-29
SI1613296T1 (sl) 2009-10-31
AU2004228782A1 (en) 2004-10-21
CY1109295T1 (el) 2014-07-02
CA2523188C (en) 2012-09-25
FR15C0054I1 (fr) 2015-11-09
CN102274517B (zh) 2018-08-31
NO20054640D0 (no) 2005-10-10
NZ542910A (en) 2007-10-26
IL216403A0 (en) 2011-12-29
US20150150833A1 (en) 2015-06-04
KR20060010745A (ko) 2006-02-02
RU2005131422A (ru) 2006-04-27
JP2013067647A (ja) 2013-04-18
ES2454272T3 (es) 2014-04-10
CN1771030A (zh) 2006-05-10
NO20131417L (no) 2005-12-09
EP1613296A2 (en) 2006-01-11
CY2015025I1 (el) 2016-04-13
PL1613296T3 (pl) 2009-12-31
WO2004089353A2 (en) 2004-10-21
DK1613296T3 (da) 2009-10-05
NO2015018I1 (no) 2015-08-03
WO2004089353A8 (en) 2005-09-01
RU2342929C2 (ru) 2009-01-10
US9492410B2 (en) 2016-11-15
PT2070526E (pt) 2014-03-31
HUS1500043I1 (hu) 2018-11-28
US20130053368A1 (en) 2013-02-28
KR20110070929A (ko) 2011-06-24
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
WO2004089353A3 (en) 2004-12-16
PT1613296E (pt) 2009-07-30
LU92782I2 (fr) 2015-09-22
NO2015018I2 (no) 2015-07-23
PL2070526T3 (pl) 2014-08-29
IL171331A (en) 2012-03-29
JP2006522800A (ja) 2006-10-05
NO334316B1 (no) 2014-02-03
TW200505423A (en) 2005-02-16
CA2523188A1 (en) 2004-10-21
TWI340640B (en) 2011-04-21
FR15C0054I2 (fr) 2018-01-26
AU2004228782B2 (en) 2010-05-20
BRPI0409364A (pt) 2006-04-25
US8283380B2 (en) 2012-10-09
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
US8901176B2 (en) 2014-12-02
DK2070526T3 (da) 2014-03-24
EP2070526B1 (en) 2014-02-26
ES2326373T3 (es) 2009-10-08
CN102274517A (zh) 2011-12-14
ATE435012T1 (de) 2009-07-15
EP1613296B1 (en) 2009-07-01
NL300752I2 (es) 2016-07-05
KR101129015B1 (ko) 2012-04-20
MXPA05010873A (es) 2006-03-21
NO335537B1 (no) 2014-12-22
EP2070526A1 (en) 2009-06-17
SI2070526T1 (sl) 2014-05-30
CY2015025I2 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
CY1115286T1 (el) Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR134835A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ECSP066268A (es) Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares
AR060089A1 (es) Tratamiento del dolor
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
MX2009005798A (es) Recuperacion de apoplejia.
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
BRPI0607536A2 (pt) tratamento de dor
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal

Legal Events

Date Code Title Description
FB Suspension of granting procedure